rheumatic diseases

The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.

People Transfer

Premium

Fate Therapeutics names Ken Batchelor CSO; SV Life Sciences' Ross and MedImmune Ventures' Amprey join NKT Therapeutics board

NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.